Methylomics and Cancer: the Current State of Methylation Profiling and Marker Development for Clinical Care

Overview

Journal Cancer Cell Int

Publisher Biomed Central

Date 2023 Oct 15

PMID 37840147

Authors

Chengyin Liu

Han Tang

Nana Hu

Tianbao Li

Affiliations

Soon will be listed here.

Abstract

Epigenetic modifications have long been recognized as an essential level in transcriptional regulation linking behavior and environmental conditions or stimuli with biological processes and disease development. Among them, methylation is the most abundant of these reversible epigenetic marks, predominantly occurring on DNA, RNA, and histones. Methylation modification is intimately involved in regulating gene transcription and cell differentiation, while aberrant methylation status has been linked with cancer development in several malignancies. Early detection and precise restoration of dysregulated methylation form the basis for several epigenetics-based therapeutic strategies. In this review, we summarize the current basic understanding of the regulation and mechanisms responsible for methylation modification and cover several cutting-edge research techniques for detecting methylation across the genome and transcriptome. We then explore recent advances in clinical diagnostic applications of methylation markers of various cancers and address the current state and future prospects of methylation modifications in therapies for different diseases, especially comparing pharmacological methylase/demethylase inhibitors with the CRISPRoff/on methylation editing systems. This review thus provides a resource for understanding the emerging role of epigenetic methylation in cancer, the use of methylation-based biomarkers in cancer detection, and novel methylation-targeted drugs.

Citing Articles

Investigation methylation status of tumor suppressor gene and and frequency of rs1569686 polymorphism of gene in patients with acute myeloid leukemia.

Rahmani B, Rostami S, Mortazavi Y, Soleiman Soltanpour M Mol Biol Res Commun. 2025; 14(2):149-156.

PMID: 40028473 PMC: 11865936. DOI: 10.22099/mbrc.2024.51563.2058.

HOXA9 methylation is not associated with survival in Brazilian patients with lung adenocarcinoma.

Vicente A, de Souza Santos F, Hirai W, Lissa D, de Oliveira Cavagna R, da Silva A Clin Epigenetics. 2025; 17(1):25.

PMID: 39962529 PMC: 11834317. DOI: 10.1186/s13148-025-01831-1.

Tumor dormancy and relapse: understanding the molecular mechanisms of cancer recurrence.

Tufail M, Jiang C, Li N Mil Med Res. 2025; 12(1):7.

PMID: 39934876 PMC: 11812268. DOI: 10.1186/s40779-025-00595-2.

Mechanisms and technologies in cancer epigenetics.

Sherif Z, Ogunwobi O, Ressom H Front Oncol. 2025; 14:1513654.

PMID: 39839798 PMC: 11746123. DOI: 10.3389/fonc.2024.1513654.

Genome-wide methylation profiling differentiates benign from aggressive and metastatic pituitary neuroendocrine tumors.

Jotanovic J, Boldt H, Burton M, Andersen M, Bengtsson D, Bontell T Acta Neuropathol. 2024; 148(1):68.

PMID: 39580368 PMC: 11585505. DOI: 10.1007/s00401-024-02836-5.

References

Raine A, Manlig E, Wahlberg P, Syvanen A, Nordlund J . SPlinted Ligation Adapter Tagging (SPLAT), a novel library preparation method for whole genome bisulphite sequencing. Nucleic Acids Res. 2016; 45(6):e36. PMC: 5389478. DOI: 10.1093/nar/gkw1110. View

Farooqi A, Fayyaz S, Poltronieri P, Calin G, Mallardo M . Epigenetic deregulation in cancer: Enzyme players and non-coding RNAs. Semin Cancer Biol. 2020; 83:197-207. DOI: 10.1016/j.semcancer.2020.07.013. View

Baylin S, Jones P . A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer. 2011; 11(10):726-34. PMC: 3307543. DOI: 10.1038/nrc3130. View

Muller S, Nebe-von-Caron G . Functional single-cell analyses: flow cytometry and cell sorting of microbial populations and communities. FEMS Microbiol Rev. 2010; 34(4):554-87. DOI: 10.1111/j.1574-6976.2010.00214.x. View

Gou D, Liu R, Shan X, Deng H, Chen C, Xiang J . Gluconeogenic enzyme PCK1 supports S-adenosylmethionine biosynthesis and promotes H3K9me3 modification to suppress hepatocellular carcinoma progression. J Clin Invest. 2023; 133(13). PMC: 10313362. DOI: 10.1172/JCI161713. View

Dong S, Li W, Wang L, Hu J, Song Y, Zhang B . Histone-Related Genes Are Hypermethylated in Lung Cancer and Hypermethylated Could Serve as a Pan-Cancer Biomarker. Cancer Res. 2019; 79(24):6101-6112. DOI: 10.1158/0008-5472.CAN-19-1019. View

Yu J, Chai P, Xie M, Ge S, Ruan J, Fan X . Histone lactylation drives oncogenesis by facilitating mA reader protein YTHDF2 expression in ocular melanoma. Genome Biol. 2021; 22(1):85. PMC: 7962360. DOI: 10.1186/s13059-021-02308-z. View

Xu W, Xu M, Wang L, Zhou W, Xiang R, Shi Y . Integrative analysis of DNA methylation and gene expression identified cervical cancer-specific diagnostic biomarkers. Signal Transduct Target Ther. 2019; 4:55. PMC: 6908647. DOI: 10.1038/s41392-019-0081-6. View

Saghafinia S, Mina M, Riggi N, Hanahan D, Ciriello G . Pan-Cancer Landscape of Aberrant DNA Methylation across Human Tumors. Cell Rep. 2018; 25(4):1066-1080.e8. DOI: 10.1016/j.celrep.2018.09.082. View

10.

Sun W, Ma G, Zhang L, Wang P, Zhang N, Wu Z . DNMT3A-mediated silence in ADAMTS9 expression is restored by RNF180 to inhibit viability and motility in gastric cancer cells. Cell Death Dis. 2021; 12(5):428. PMC: 8087691. DOI: 10.1038/s41419-021-03628-5. View

11.

Ren J, Lu P, Zhou X, Liao Y, Liu X, Li J . Genome-Scale Methylation Analysis of Circulating Cell-Free DNA in Gastric Cancer Patients. Clin Chem. 2021; 68(2):354-364. DOI: 10.1093/clinchem/hvab204. View

12.

Dawson M, Kouzarides T . Cancer epigenetics: from mechanism to therapy. Cell. 2012; 150(1):12-27. DOI: 10.1016/j.cell.2012.06.013. View

13.

Du J, Johnson L, Jacobsen S, Patel D . DNA methylation pathways and their crosstalk with histone methylation. Nat Rev Mol Cell Biol. 2015; 16(9):519-32. PMC: 4672940. DOI: 10.1038/nrm4043. View

14.

Miller K, Siegel R, Lin C, Mariotto A, Kramer J, Rowland J . Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016; 66(4):271-89. DOI: 10.3322/caac.21349. View

15.

Oussalah A, Rischer S, Bensenane M, Conroy G, Filhine-Tresarrieu P, Debard R . Plasma mSEPT9: A Novel Circulating Cell-free DNA-Based Epigenetic Biomarker to Diagnose Hepatocellular Carcinoma. EBioMedicine. 2018; 30:138-147. PMC: 5952996. DOI: 10.1016/j.ebiom.2018.03.029. View

16.

Han Y, Ji L, Guan Y, Ma M, Li P, Xue Y . An epigenomic landscape of cervical intraepithelial neoplasia and cervical cancer using single-base resolution methylome and hydroxymethylome. Clin Transl Med. 2021; 11(7):e498. PMC: 8288011. DOI: 10.1002/ctm2.498. View

17.

Shimizu M, Koma Y, Sakamoto H, Tsukamoto S, Kitamura Y, Urakami S . Metallothionein 2A Expression in Cancer-Associated Fibroblasts and Cancer Cells Promotes Esophageal Squamous Cell Carcinoma Progression. Cancers (Basel). 2021; 13(18). PMC: 8464741. DOI: 10.3390/cancers13184552. View

18.

Hou Y, Guo H, Cao C, Li X, Hu B, Zhu P . Single-cell triple omics sequencing reveals genetic, epigenetic, and transcriptomic heterogeneity in hepatocellular carcinomas. Cell Res. 2016; 26(3):304-19. PMC: 4783472. DOI: 10.1038/cr.2016.23. View

19.

Su J, Wu G, Ye Y, Zhang J, Zeng L, Huang X . NSUN2-mediated RNA 5-methylcytosine promotes esophageal squamous cell carcinoma progression via LIN28B-dependent GRB2 mRNA stabilization. Oncogene. 2021; 40(39):5814-5828. PMC: 8484015. DOI: 10.1038/s41388-021-01978-0. View

20.

Black J, Van Rechem C, Whetstine J . Histone lysine methylation dynamics: establishment, regulation, and biological impact. Mol Cell. 2012; 48(4):491-507. PMC: 3861058. DOI: 10.1016/j.molcel.2012.11.006. View